Incyte is a U.S. biopharmaceutical company focused on oncology and inflammatory diseases. Its best-known product is Jakafi (ruxolitinib), used in certain blood cancers and related conditions, and it markets additional therapies while advancing a pipeline of small molecules and biologics. Physicians and patients in specialty care are the primary end users, with revenue driven largely by branded prescription medicines.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 1,215.5 | — | 405 | — |
| Q3 2025 | 1,366 | — | 424.2 | 105.8% |
| Q4 2025 | 1,506.8 | — | 299.3 | 8.6% |
| Q1 2026 | 1,272.7 | — | 303.3 | 35.1% |
| Q2 2026 | 1,674 | 37.7% | 585.6 | 44.6% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: United Therapeutics Corporation (UTHR), Formula One Group (FWONK), Genmab A/S (GMAB), Expand Energy Corporation (EXE), Tower Semiconductor Ltd. (TSEM), BioNTech SE (BNTX)